


WHAT IS CLAIMED:

1. A compound of Formula I:



a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein

=A-B= is =C(R⁴)-C(R⁵)= and -X=Y- is -C(R⁶)=N-, -N=C(R⁷)-, -N=N- or -S-, or


=A-B= is =N-C(R⁵)= and -X=Y- is -N=C(R⁷)-, -C(R⁶)=N-, -S- or -O-, or

=A-B= is =C(R⁴)-N= and -X=Y- is -C(R⁶)=N-, -S- or -O-, or

=A-B= is =N-N= and -X=Y- is -S- or -O-, or


=A-B= is =C(R⁴)- and -X=Y- is -S-N=, -N(R¹⁰)-N=, or


=A-B= is -C(R⁴)= and -X=Y- is =N-S-, or =N-N(R¹⁰)-;



R¹ is H or -(C₁-C₆)alkyl;

R² is H, -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl or -(C₁-C₆)alkyl(C₃-C₇)cycloalkyl;





Q is $-\text{OR}^{13}$, or $-\text{NR}^{13}\text{R}^{14}$;

j is 1 or 2;

k is 0, 1 or 2;

l is 0, 1 or 2;

m is 0, 1 or 2;

R^4 , R^5 , R^6 and R^7 may be the same or different, and are independently selected from the group consisting of H, $-\text{OH}$, halogen, polyhaloalkyl, $-(\text{C}_1-\text{C}_6)\text{alkyl}$, $-(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{CN}$, $\text{NR}^{10}\text{R}^{11}$, $\text{NR}^{13}\text{R}^{14}$, $-\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}$, $-\text{O}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{S}(\text{C}_1-\text{C}_6)\text{alkyl}$, $-\text{S}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$ and $-\text{S}(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$;

R^8 is 1 to 3 substituents, which may be the same or different, and are independently selected from the group consisting of H, halogen, $-\text{OH}$, polyhaloalkyl, polyhaloalkoxy, $-\text{CN}$, $-\text{NO}_2$, $-(\text{C}_1-\text{C}_6)\text{alkyl}$, $-(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $\text{NR}^{10}\text{R}^{11}$, $\text{NR}^{13}\text{R}^{14}$, $-\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}$, $-\text{O}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{O}(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$ and $-\text{CONR}^{13}\text{R}^{14}$;

R^9 is $-\text{SO}_2(\text{C}_1-\text{C}_6)\text{alkyl}$, $-\text{SO}_2(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{SO}_2(\text{C}_1-\text{C}_6)\text{alkyl}(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, $-\text{SO}_2(\text{C}_1-\text{C}_6)\text{polyhaloalkyl}$, $-\text{SO}_2[\text{hydroxy}(\text{C}_2-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2[\text{amino}(\text{C}_2-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2[\text{alkoxy}(\text{C}_2-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2[\text{alkylamino}(\text{C}_2-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2[\text{dialkylamino}(\text{C}_2-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2(\text{aryl})$, $-\text{SO}_2(\text{heteroaryl})$, $-\text{SO}_2[\text{aryl}(\text{C}_1-\text{C}_6)\text{alkyl}]$, $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$, $-\text{CO}(\text{C}_1-\text{C}_6)\text{alkyl}$,

-CO(C₃-C₇)cycloalkyl, -CO(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, CO(C₁-C₆)polyhaloalkyl, -C(O)aryl, -C(O)heteroaryl, -CONR¹³R¹⁴, -C(S)NR¹³R¹⁴, aryl, heteroaryl, -(CH₂)CONR¹³R¹⁴, -C(=NCN)alkylthio, -C(=NCN)NR¹³R¹⁴, -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -(C₁-C₆)alkylaryl, -(C₁-C₆)alkylheteroaryl or -COOR¹²;

R¹⁰ is H or alkyl;



R¹¹ is H, -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, aryl, heteroaryl, -SO₂(C₁-C₆)alkyl, -SO₂(C₃-C₇)cycloalkyl, -SO₂(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -SO₂(C₁-C₆)polyhaloalkyl, -SO₂(aryl), -SO₂(heteroaryl), -CO(C₁-C₆)alkyl, -CO(C₃-C₇)cycloalkyl, -CO(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -C(O)aryl, -C(O)heteroaryl, -CONR¹³R¹⁴ or -COOR¹²;

R¹² is (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -(C₁-C₆)alkylaryl, -(C₁-C₆)alkylheteroaryl, aryl or heteroaryl;

R¹³ and R¹⁴ may be the same or different and are independently H, -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -(C₁-C₆)alkylaryl, aryl or heteroaryl; and,

R¹⁵ is one or two substituents, which may be the same or different, and are independently H, -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, aryl, heteroaryl, -CN, -CONR¹³R¹⁴, -COOR¹³, -OH, -O(C₁-C₆)alkyl, -O(C₃-C₇)cycloalkyl, -O(C₁-C₆)alkyl(C₃-C₇)cycloalkyl, -NR¹⁰R¹¹, -NR¹³R¹⁴, or a -(C₁-C₆)alkyl group substituted by an aryl, heteroaryl, hydroxy, alkoxy, -NR¹⁰R¹¹, -NR¹³R¹⁴, -CONR¹³R¹⁴, or -COOR¹³ group, provided that a chemically stable compound results from substitution by R¹⁵.

2. A compound as defined in Claim 1 wherein the heterocyclic group attached to Z is



3. A compound as defined in Claim 2 wherein
- R^1 is hydrogen,
- R^2 is hydrogen or (C_1-C_6) alkyl,
- R^4 , R^5 , R^6 and R^7 are hydrogen or halogen,
- R^8 is 1 to 3 substituents, which may be the same or different, and are
- independently selected from the group consisting of H, halogen, $-O(C_1-C_6)$ alkyl, $-OH$, polyhaloalkyl and polyhaloalkoxy,
- R^9 is $-SO_2(C_1-C_6)$ alkyl, $-SO_2(C_3-C_7)$ cycloalkyl, $-SO_2(C_1-C_6)$ alkyl(C_3-C_7)cycloalkyl, $-SO_2$ aryl, $-SO_2$ heteroaryl, $-SO_2NR^{13}R^{14}$, $-CO(C_1-C_6)$ alkyl, $-CO(C_3-C_7)$ cycloalkyl, $-CO(C_1-C_6)$ alkyl(C_3-C_7)cycloalkyl, $-C(O)$ aryl, $-C(O)$ heteroaryl, aryl, heteroaryl,
- R^{10} is H or $-(C_1-C_6)$ alkyl,
- R^{11} is $-SO_2(C_1-C_6)$ alkyl, Q is $-OR^{13}$ or $-NR^{13}R^{14}$;


R^{13} and R^{14} may be the same or different, and are independently H or $-(C_1-C_6)alkyl$;

the sum of j and k is 2 or 3; and,

the sum of l and m is 2 or 3.

5

4. A compound as defined in Claim 3 wherein




R^9 is $-SO_2(C_1-C_6)alkyl$, $-SO_2(C_3-C_7)cycloalkyl$, $-SO_2aryl$, $-SO_2heteroaryl$, $-CO(C_1-C_6)alkyl$, $-CO(C_3-C_7)cycloalkyl$, $-CO(C_1-C_6)alkyl(C_3-C_7)cycloalkyl$, $-C(O)aryl$, $-C(O)heteroaryl$, $aryl$, or $heteroaryl$, and

10

the sum of j and k is 2 or 3.


5. The compound as defined in Claim 1 of the formula





















15






a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

20 wherein R^9 is as shown in the table below:


Example	R^9
1	
3	$-SO_2CH_3$

Example	R ⁹
4	
1G	
1H	
1I	
3E	
3F	
3G	
3H	
4B	

Example	R ⁹
4C	
4D	
4E	
4F	
4G	
4H	
4I	
4J	
4K	








Example	R ⁹
4L	
4M	
4N	
4O	
4P	




6. The compound as defined in Claim 1 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
3I	-SO ₂ CH ₃
3J	
3K	
3L	
4Z	
4AA	
4BB	
4CC	


Example	R ⁹
4DD	
4EE	
4FF	

7. The compound as defined in Claim 1 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

10 wherein R⁹ is as shown in the table below:

Example	R ⁹
3N	-SO ₂ CH ₃
3O	







8. The compound as defined in Claim 1 of the formula



- 5 a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,


wherein R⁹ is as shown in the table below:

Example	R ⁹
5	
5A	-SO ₂ CH ₃
5B	
5C	
5D	
5E	

Example	R ⁹
5F	
5G	
5H	
5I	
5J	
5K	





9. The compound as defined in Claim 3 of the formula

5




a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
5M	-SO ₂ CH ₃
5N	
5O	
5P	
5Q	




5

10. The compound as defined in Claim 1 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
6	
6B	-SO ₂ CH ₃
6C	
6D	



5











11. The compound as defined in Claim 1 of the formula




10 a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein Z and R⁹ are as shown in the table below:

Example	Z	R ⁹
7		










Example	Z	R ⁹
7B		-SO ₂ CH ₃
7C		
7D		
7E		
7F		-SO ₂ CH ₃
7G		









12. The compound as defined in Claim 1 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:


Example	R ⁹
10	
10A	
10B	
10C	
10D	
10E	
10F	
10G	
10H	

Example	R ⁹
10I	
10J	
10K	
10L	
10M	
10N	
10O	
10P	

1002634-1-1001

Example	R ⁹
10Q	
10W	-SO ₂ CH ₃




13. The compound as defined in Claim 1 of the formula




5

a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
10S	-SO ₂ CH ₃
10T	
10U	
10V	













14. The compound as defined in Claim 1 of the formula




























a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,




10 wherein Z and R⁹ are as shown in the table below:

Example	Z	R ⁹
10X		-SO ₂ CH ₃
10Y		
10Z		
10AA		


Example	Z	R ⁹
10BB		
10CC		
10DD		
10EE		
10FF		
10GG		

Example	Z	R ⁹
10HH		
10II		
10JJ		
10KK		
10LL		
10MM		
10NN		

Example	Z	R ⁹
1000		
10PP		
10QQ		
10RR		
11		-SO ₂ CH ₃
11A		-SO ₂ CH ₃
11B		-SO ₂ CH ₃

Example	Z	R ⁹
11C		-SO ₂ CH ₃
11D		-SO ₂ CH ₃
11E		-SO ₂ CH ₃

15. The compound as defined in Claim 1 of the formula
















5

a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,


wherein R⁹ is as shown in the table below:

Example	R ⁹
19	-SO ₂ CH ₃

Example	R ⁹
19A	
19B	
19C	
19D	
19E	
19F	
19G	
19H	
19I	
19J	

Example	R ⁹
19K	
19L	
19M	


16. The compound as defined in Claim 1 of the formula




5


a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
24	
24A	-SO ₂ CH ₃

Example	R ⁹
24B	



17. The compound as defined in Claim 1 of the formula



5


a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein R⁹ is as shown in the table below:

Example	R ⁹
25	
26	
27	-SO ₂ CH ₃













10















18. The compound as defined in Claim 1 of the formula







a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,


wherein Z and R⁹ are as shown in the table below:

Example	Z	R ⁹
12		-SO ₂ CH ₃
12A		-SO ₂ CH ₃
12B		
12C		
12D		
12E		
12F		

Example	Z	R ⁹
12G		
12H		
12I		
12J		
12K		
12L		
12M		

Example	Z	R ⁹
12N		
16		






19. The compound as defined in Claim 1 of the formula




5

a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

10 wherein Z and R⁹ are as shown in the table below:

Example	Z	R ⁹
20		
21		
22		-SO ₂ CH ₃





20. The compound as defined in Claim 1 of the formula



- 5 a prodrug thereof, or a pharmaceutically acceptable salt and/or hydrate of said compound or of said prodrug, or where applicable, a geometric or optical isomer or racemic mixture thereof,

wherein Z and R⁹ are as shown in the table below:

Example	Z	R ⁹
23		
23A		-SO ₂ CH ₃
23B		
23C		
23D		

Example	Z	R ⁹
23E		
23F		

21. A pharmaceutical composition which comprises an effective amount of a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

22. A method of treating eating and metabolic disorders comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.

23. The method of Claim 22 wherein said eating disorder is hyperphagia.

24. The method of Claim 22 wherein said metabolic disorder is obesity.

25. A method of treating disorders associated with obesity comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a prodrug thereof or a pharmaceutically acceptable salt of said compound or of said prodrug.

26. The method of Claim 25 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

27. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

5 a second compound, said second compound being a β_3 agonist, a thryomimetic agent, an eating behavior modifying agent or an NPY antagonist; and

a pharmaceutically acceptable carrier therefor.

28. A method of treating an eating disorder which comprises administering
10 to a mammal in need of such treatment

an amount of a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

15 a second compound, said second compound being a β_3 agonist, a thryomimetic agent, an eating behavior modifying agent or an NPY antagonist;

wherein the amounts of the first and second compounds result in a therapeutic effect.

29. A pharmaceutical composition which comprises a therapeutically
20 effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

25 a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, metformin, acarbose, a thiazolidinedione such as troglitazone or rezulin; a

glitazone such as rosiglitazone or pioglitazone; a sulfonylurea, glipazide, glyburide, or chlorpropamide; and

a pharmaceutically acceptable carrier therefor.

5 30. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier therefor.

 31. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.